Welcome to our dedicated page for Heartbeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartBeam, Inc. filings document material events for a Nasdaq-listed medical technology issuer with common stock under BEAT and warrants under BEATW. Its 8-K disclosures cover underwriting agreements and common-stock offering terms, emerging growth company status, and FDA-related correspondence for its 12-Lead ECG Synthesis Software.
These records also identify capital-structure changes and formal event disclosures tied to commercialization and regulatory development of HeartBeam's 3D ECG technology.
HeartBeam, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on July 31, 2026. Shareholders will vote to elect nine directors, ratify CBIZ CPAs P.C. as auditor and consider an amendment to the 2022 Equity Incentive Plan to increase authorized shares by 3,000,000. The record date for voting is June 5, 2026 and there were 55,506,835 shares outstanding as of that date. The board recommends voting FOR each proposal. The amendment would raise the 2022 Plan cap from 11,900,000 to 14,900,000 shares; current awards include 501,488 RSUs and 9,979,532 options outstanding, and 6,542,707 shares remain available for grant as of the record date.
HeartBeam, Inc. reported another quarter of losses with no revenue and highlighted serious liquidity concerns. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.7 million, narrower than the $5.5 million loss a year earlier. Operating expenses were $4.7 million, with selling, general and administrative costs rising 17% and research and development falling 32% as product development and consulting spending declined.
Cash and cash equivalents were $2.0 million as of March 31, 2026, and management stated this is insufficient to fund operations for the next twelve months, raising “substantial doubt” about the company’s ability to continue as a going concern. Subsequent to quarter-end, HeartBeam completed an underwritten offering of 14,375,000 shares of common stock for gross proceeds of approximately $11.5 million. The company remains pre-revenue despite FDA clearances for its 3D ECG telehealth system and is beginning a limited commercial launch and multiple pilot studies, while expecting no material commercial revenue in 2026.
HeartBeam, Inc. director Richard Ferrari increased his stake by purchasing 57,500 shares of common stock at $0.80 per share. The buy was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners acted as sole bookrunner.
This amended Form 4 corrects Ferrari’s previously reported acquisition and total beneficial ownership. The original filing mistakenly showed 62,500 shares acquired; the correct figure is 57,500 shares. Following this transaction, Ferrari beneficially owns 286,636 shares of HeartBeam common stock directly.
HeartBeam, Inc. CFO Tim Cruickshank increased his stake by buying 31,250 shares of common stock at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock.
The offering priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. After this transaction, Cruickshank directly owns 72,230 shares, including 23,333 RSUs that have vested.
HeartBeam, Inc. director Willem Elfrink reported an open-market purchase of common stock. On April 16, 2026, he bought 187,500 shares at $0.80 per share, bringing his direct holdings to 538,667 shares.
According to the footnote, these shares were purchased in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners acting as sole bookrunner.
HeartBeam, Inc. director-associated entity Open Book Healthcare purchased 31,250 shares of common stock in an open-market transaction on April 16, 2026, at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. Following this transaction, 31,250 shares are held indirectly for the benefit of Michael R. Jaff through Open Book Healthcare.
HeartBeam, Inc. director Branislav Vajdic made an open-market purchase of 31,250 shares of common stock at $0.80 per share. After this transaction, he directly owns 909,914 shares.
The shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners, a division of American Capital Partners, acted as sole bookrunner. The offering priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director Richard Ferrari reported an open-market purchase of 62,500 shares of common stock at $0.80 per share. Following this buy, he directly holds 291,636 shares. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, which priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. President Robert Paul Eno reported an open-market purchase of common stock. On April 16, 2026, he bought 12,500 shares at $0.80 per share, increasing his direct holdings to 36,742 shares.
The purchased shares were acquired in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. His reported holdings include 23,333 RSUs that have vested as referenced in a prior Form 4 filing.
HeartBeam, Inc. director Marga Ortigas-Wedekind purchased 25,000 shares of Common Stock on April 16, 2026 in an open-market transaction at $0.80 per share, bringing her direct holdings to 137,293 shares.
According to a footnote, these shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, acted as the sole bookrunner for this offering, which priced on April 14, 2026 and closed on April 16, 2026.